Evaluating the Economic Impact of Project ECHO Diabetes: Cost Savings From HbA1c Reduction in Type 1 and Type 2 Diabetes
Authors' conclusion
Project ECHO Diabetes achieved substantial cost savings through improved glycemic control, supporting its broader implementation to enhance diabetes care and reduce health care costs.
Study context
- Population
- Adults with T1D or T2D at Federally Qualified Health Centers in California and Florida, 2021–2022
- Participants
- 32,796 adults
- Comparison
- Before vs after Project ECHO Diabetes tele-education
- T1Dn = 1,127
- T2Dn = 31,669
- Outcome
- Health care cost savings from HbA1c reductions >9% and comparison with program costs
Methodological detailsbefore and after 6-month intervention, Federally Qualified Health Centers, California and Florida, Intervention: bimonthly tele-education sessions, real-time medical support and access to diabetes management resources over 6 months
- Before and after 6-month intervention
- Federally Qualified Health Centers, California and Florida
- Intervention: bimonthly tele-education sessions, real-time medical support and access to diabetes management resources over 6 months
Main finding
As reported in the abstract
Health care cost savings vs program costs · first year
Estimated first-year per-patient savings
$3205.95
Total program savings
exceeding $5 million
Implementation costs
$513,257
Further findings
Proportion with HbA1c >9%, before vs after · 6 months
- T1D: decreased from
- 31.7% to 26.7%
- T2D: decreased from
- 24.0% to 18.9%
Original publication
Evaluating the Economic Impact of Project ECHO Diabetes: Cost Savings From HbA1c Reduction in Type 1 and Type 2 Diabetes. Endocr Pract. Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →